Precision-engineered cancer immunotherapies like CAR T-cell approaches aim to empower the patient’s own immune system to target and eliminate cancer.  With >70% of CAR T therapy clinical trials targeted towards liquid tumors, accurately assessing real-time cell killing in suspension tumor cells is an essential part of testing these therapies.

In this application note, you will explore:

  • Successful immobilization of suspension tumor cells for generating accurate impedance measurements
  • How CytoTronics’ electrical imaging platform enables non-destructive monitoring of immune-mediated cytotoxicity in suspension tumor cells over time
  • Quantitative, time-resolved data capturing CAR T-cell activity across a range of effector-to-target (E:T) ratios

Measuring the effects of CAR T-cell treatment on cancer cells at different E:T ratios.